U.S. RESEARCH ROUNDUP- Enliven Therapeutics, Lululemon Athletica, Walgreens

89bio

29/03/2023 08:03

March 29 (Reuters) - Wall Street securities analysts revised their ratings and price
targets on several U.S.-listed companies, including Enliven Therapeutics, Lululemon Athletica
and Walgreens on Wednesday. 
    
    HIGHLIGHTS
                 * Enliven Therapeutics Inc  ELVN.O : Jefferies initiates with buy rating; price
 target $27
 
                 * Lululemon Athletica Inc  LULU.O : KeyBanc raises target price to $390 from
 $375
 
                 * Walgreens  WBA.O : JP Morgan raises target price to $43 from $40
 
            
Following is a summary of research actions on U.S. companies reported by Reuters on Wednesday.
Stock entries are in alphabetical order. 
    
                 * 89Bio Inc  ETNB.O : SVB Securities raises target price to $34 from $29
 
                 * Aadi Bioscience Inc  AADI.O : Jefferies cuts target price to $37 from $45
 
                 * Biomea Fusion Inc  BMEA.O : Jefferies raises target price to $36 from $19
 
                 * Core & Main Inc  CNM.N : RBC raises target price to $26 from $24
 
                 * Dermtech Inc  DMTK.O : TD Cowen cuts target price to $6 from $8
 
                 * Endra Life Sciences Inc  NDRA.O : Ascendiant Capital cuts target price to $30
 from $85
 
                 * Enliven Therapeutics Inc  ELVN.O : Jefferies initiates with buy rating; price
 target $27
 
                 * Fiscalnote Holdings Inc  NOTE.N : D.A. Davidson cuts target price to $1.75
 from $2.50
 
                 * Freightcar America Inc  RAIL.O : Stephens cuts target price to $3 from $4
 
                 * Icad Inc  ICAD.O : BTIG cuts target price to $3 from $4
 
                 * Intapp Inc  INTA.O : Credit Suisse raises target price to $48 from $40
 
                 * Intra-Cellular Therapies Inc  ITCI.O : Canaccord Genuity raises PT to $98 from
 $93
 
                 * Jounce Therapeutics Inc  JNCE.O : Baird cuts target price to $2 from $4
 
                 * Lululemon Athletica Inc  LULU.O : KeyBanc raises target price to $390 from
 $375
 
                 * Progress Software Corp  PRGS.O : Jefferies raises target price to $60 from $55
 
                 * Progress Software Corp  PRGS.O : JP Morgan raises target price to $65 from $57
 
                 * Regal Rexnord Corp  RRX.N : Baird cuts target price to $184 from $188
 
                 * Shift Technologies Inc  SFT.O : D.A. Davidson raises target price to $1 from
 $0.25
 
                 * Somalogic Inc  SLGC.O : Canaccord Genuity cuts target price to $5 from $6
 
                 * Somalogic Inc  SLGC.O : TD Cowen cuts target price to $7 from $8
 
                 * Sovos Brands Inc  SOVO.O : Piper Sandler raises target price to $19 from $17
 
                 * Sunrun Inc  RUN.O : RBC cuts target price to $34 from $42
 
                 * Taysha Gene Therapies Inc  TSHA.O : Truist Securities cuts target price to $3
 from $4
 
                 * TD Synnex Corp  SNX.N : JP Morgan cuts target price to $115 from $125
 
                 * TD Synnex Corp  SNX.N : Raymond James cuts target price to $130 from $140
 
                 * Tegna Inc  TGNA.N : Wells Fargo cuts target price to $18 from $20
 
                 * Terns Pharmaceuticals Inc  TERN.O : JP Morgan raises target price to $9 from
 $6
 
                 * Uipath Inc  PATH.N : RBC raises target price to $18 from $17
 
                 * Viking Therapeutics Inc  VKTX.O : BTIG raises target price to $31 from $20
 
                 * Viking Therapeutics Inc  VKTX.O : Truist Securities raises target price to $32
 from $28
 
                 * Walgreens  WBA.O : JP Morgan raises target price to $43 from $40
 
    
  

 (Compiled by Bengaluru Newsroom)
 ((Diaries@thomsonreuters.com))